X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: University of Montreal
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2020
Details:
University of Montreal/IRICoR will conduct and finance the research program until the license is exercised. Ipsen would assume all development activities and commercialize the drug candidate globally.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
